{"id":195815,"date":"2010-01-18T18:42:20","date_gmt":"2010-01-18T23:42:20","guid":{"rendered":"http:\/\/www.blisstree.com\/?p=139465"},"modified":"2010-01-18T18:42:20","modified_gmt":"2010-01-18T23:42:20","slug":"test-to-help-with-breast-cancer-decisions","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/195815","title":{"rendered":"Test to Help with Breast Cancer Decisions"},"content":{"rendered":"<p>The decision on whether to treat early-stage <a href=\"http:\/\/www.blisstree.com\/articles\/mighty-mango-prevents-breast-cancer-in-lab\/\">breast cancer<\/a> with chemotherapy can be difficult for many women, but a 21-gene test is helping to make that decision easier for doctors and patients alike.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-139476\" src=\"http:\/\/images3.blisstree.com\/files\/2010\/01\/decision-help.jpg\" alt=\"decision-help\" width=\"500\" height=\"215\" \/><\/p>\n<p>The multigene test called <strong>Oncotype DX<\/strong> is produced by Genomic Health Inc. It analyzes 21 genes taken from a tumor sample to see how active they are. A test result may range from 0 to 100. Since their cancer is considered less likely to recur, women who have low scores may decide not to use chemotherapy. Oncotype DX is intended for women with<strong> estrogen receptor-positive <a href=\"http:\/\/www.blisstree.com\/articles\/storing-breast-milk\/\">breast<\/a> cancer<\/strong> that hasn&#8217;t spread to lymph nodes. Around 100,000 such cases are diagnosed every year. More than 120,000 breast cancer patients have used the Oncotype DX test since it became available in 2004.<\/p>\n<p>The gene test is having a <strong>big impact on early breast cancer care<\/strong>. According to new research from <a href=\"http:\/\/loyolamedicine.org\/\">Loyola University Health System<\/a>, the test was the reason doctors changed their treatment recommendations in 31.5% of cases, and 27% of patients changed their treatment decisions because of test results. In cases where the test affected a treatment decision, the change by doctors and patients was to avoid chemotherapy. The study included 89 breast cancer patients treated by 17 medical oncologists at several different locations. The study results are published in the <em>Journal of Clinical Oncology<\/em>.<\/p>\n<p>&#8220;This is the first study to show that results from this test simultaneously impact decisions by physicians as well as patients,&#8221; said oncologist Dr. Shelly Lo, an assistant professor in the Department of Medicine, Loyola University Chicago Stritch School of Medicine.<\/p>\n<p>The Oncotype DX test costs $3,910, and often is covered by insurance. However, please check with your own insurance provider before being tested.<\/p>\n<p>(Image via <a href=\"http:\/\/www.sxc.hu\/photo\/971448\">stock.xchng<\/a>)<\/p>\n<p>Post from: <a href=\"http:\/\/www.blisstree.com\">Blisstree<\/a><\/p>\n<p><a href=\"http:\/\/www.blisstree.com\/articles\/test-to-help-with-breast-cancer-decisions\/\">Test to Help with Breast Cancer Decisions<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The decision on whether to treat early-stage breast cancer with chemotherapy can be difficult for many women, but a 21-gene test is helping to make that decision easier for doctors and patients alike. The multigene test called Oncotype DX is produced by Genomic Health Inc. It analyzes 21 genes taken from a tumor sample to [&hellip;]<\/p>\n","protected":false},"author":2832,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-195815","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/195815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2832"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=195815"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/195815\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=195815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=195815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=195815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}